*Corresponding author (e-mail: r.f.j.kullberg@amsterdamumc.nl).
†These authors contributed equally.
§Co–senior authors.

References

1. Kullberg RFJ, de Brabander J, Boers LS, Biemond JJ, Nossent EJ, Heunks LMA, *et al.*; ArtDECO consortium and the Amsterdam UMC COVID-19 Biobank Study Group. Lung microbiota of critically ill COVID-19 patients are associated with non-resolving acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2022;206: 846–856.
2. Dickson RP, Schultz MJ, van der Poll T, Schouten LR, Falkowski NR, Luth JE, *et al.*; Biomarker Analysis in Septic ICU Patients (BASIC) Consortium. Lung microbiota predict clinical outcomes in critically ill patients. *Am J Respir Crit Care Med* 2020;201:555–563.
3. Sulaiman I, Chung M, Angel L, Tsay JJ, Wu BG, Yeung ST, *et al.* Microbial signatures in the lower airways of mechanically ventilated COVID-19 patients associated with poor clinical outcome. *Nat Microbiol* 2021;6: 1245–1258.
4. Leisman DE, Mehta A, Thompson BT, Charland NC, Gonye ALK, Gushterova I, *et al.* Alveolar, endothelial, and organ injury marker dynamics in severe COVID-19. *Am J Respir Crit Care Med* 2022;205: 507–519.
5. Saris A, Reijnders TDY, Nossent EJ, Schuurman AR, Verhoeff J, Asten SV, *et al.*; ArtDECO consortium and the Amsterdam UMC COVID study group. Distinct cellular immune profiles in the airways and blood of critically ill patients with COVID-19. *Thorax* 2021;76:1010–1019.
6. Boers LS, de Brabander J, Nossent EJ, Heunks LMA, Vlaar APL, Bonta PI, *et al.*; ArtDECO consortium Amsterdam UMC COVID study group. Sustained alveolar hyperinflammatory response in critically ill COVID-19 patient [abstract]. *Am J Respir Crit Care Med* 2022;205: A3539.

Erratum: Antihistone Properties of C1 Esterase Inhibitor Protect against Lung Injury

The authors wish to inform the readers that there is an error in their article published in the July 15, 2017 issue of AJRCCM (1). It was brought to their attention that they had inadvertently duplicated a representative image in Figure 2F ($B1^{-/-}B2^{-/-}$ mice, Bleomycin + Veh) in Figure 6A (wild-type mice, Bleomycin + Veh). A revised version of Figure 6A is published here with the correct Bleomycin + Veh panel (Figure 2F, which is unchanged, is also included for comparison).

These corrections do not affect the interpretation of the data or the conclusions of the paper. The authors deeply apologize for any inconvenience caused. ■

Malgorzata Wygrecka*‡
Lukasz Wujak
Philipp Markart*
Universities of Giessen and Marburg Lung Center
Giessen, Germany

Djuro Kosanovic
Universities of Giessen and Marburg Lung Center
Giessen, Germany

Holger C. Müller-Redetzky
Martin Witzenrath
Charité-Universitätsmedizin
Berlin, Germany

Ingrid Henneke
Ralph T. Schermuly*
Werner Seeger*
Justus-Liebig University
Giessen, Germany
and
Excellence Cluster Cardio-Pulmonary System
Giessen, Germany

Liliana Schaefer
Goethe University School of Medicine, University Hospital
Frankfurt am Main, Germany

Grazyna Kwapiszewska
Leigh M. Marsh
Ludwig Boltzmann Institute for Lung Vascular Research
Graz, Austria

Nelli Baal
Institute for Clinical Immunology and Transfusion Medicine
Universities of Giessen and Marburg Lung Center
Giessen, Germany

Holger Hackstein*
University Hospital Erlangen
Erlangen, Germany

Steven de Maat
Coen Maas
University Medical Center Utrecht
Utrecht, the Netherlands

*Members of the German Center for Lung Research, Giessen, Germany.
‡Corresponding author (email: malgorzata.wygrecka@innere.med.uni-giessen.de)

Reference

1. Wygrecka M, Kosanovic D, Wujak L, Reppe K, Henneke I, Frey H, Didiasova M, Kwapiszewska G, Marsh LM, Baal N, Hackstein H, Zakrzewicz D, Müller-Redetzky HC, de Maat S, Maas C, Nolte MW, Panousis C, Schermuly RT, Seeger W, Witzenrath M, Schaefer L, Markart P. Antihistone properties of C1 esterase inhibitor protect against lung injury. *Am J Respir Crit Care Med* 2017;196:186–199.